Untargeted metabolic profiling of saliva by liquid chromatography-mass spectrometry for the identification of potential diagnostic biomarkers of asthma by Aditya Malkar (7162760) et al.
0 
 
Untargeted metabolic profiling of saliva by liquid chromatography-mass spectrometry 
for the identification of potential diagnostic biomarkers of asthma 
Aditya Malkar
1
, Emma Wilson
2
, Tim Harrrison
2
, Dominick Shaw
2*
 and Colin S. Creaser
1
*. 
1
Centre for Analytical Science, Department of Chemistry, Loughborough University, 
Loughborough, Leicestershire, LE11 3TU, UK. 
2
Respiratory Research Unit, Nottingham City Hospital, Nottingham, NG5 1PB, UK 
*Joint corresponding authors 
For correspondence: 
E-mail: C.S.Creaser@lboro.ac.uk 
Tel: +44(0)1509 222552 
Fax: +44(0)1509 223925 
 
Keywords:  Asthma, metabolite profiling, LC-MS, saliva 
  
1 
 
Abstract 
Current clinical tests employed to diagnose asthma are inaccurate and limited by their 
invasive nature. New metabolite profiling technologies offer an opportunity to improve 
asthma diagnosis using non-invasive sampling. A rapid analytical method for metabolite 
profiling of saliva is reported using ultra-high performance liquid chromatography combined 
with high resolution time-of-flight mass spectrometry (UHPLC-MS). The only sample pre-
treatment required was protein precipitation with acetonitrile. The method has been applied to 
a pilot study of saliva samples obtained by passive drool from well phenotyped patients with 
asthma and healthy controls. Stepwise data reduction and multivariate statistical analysis was 
performed on the complex dataset obtained from the UHPLC-MS analysis to identify 
potential metabolomic biomarkers of asthma in saliva. Ten discriminant features were 
identified that distinguished between moderate asthma and healthy control samples with an 
overall recognition ability of 80% during training of the model and 97% for model cross-
validation. The reported method demonstrates the potential for a non-invasive approach to the 
clinical diagnosis of asthma using mass spectrometry-based metabolic profiling of saliva. 
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1. Introduction 
Asthma is a heterogeneous disease
1
 characterised by symptoms with variable airflow 
obstruction, bronchial hyper-responsiveness and airway inflammation. The diagnosis of 
asthma in primary care is based on the presence or absence of airflow limitation, and its 
reversibility to inhaled bronchodilators, as measured by peak expiratory flow or spirometry. 
According to the guidelines, using spirometric values or peak flow as the prime outcome of 
interest is of limited value in patients with normal or near normal pre-treatment lung function 
since there is little room for measurable improvement
2
; furthermore it is estimated that 30% 
of patients with a diagnosis of asthma have no evidence of the disease.
3–5
 Biomarkers of 
airway inflammation and airway hyperresponsiveness obtained from various invasive and 
non-invasive physiological sources such as sputum, blood, serum, urine, and exhaled breath 
have been used to diagnose of asthma.
6
 These tests differ in their sensitivity, specificity and 
patient acceptance. More importantly they cannot be used below certain lung function 
thresholds or ages, limiting their application and widespread adoption. Consequently there is 
a need for a simple, non-invasive procedure for the accurate identification of asthma.
7
 
Metabolic profiling is the systematic study of chemical fingerprints of low molecular mass 
endogenous metabolites, known as the metabolome; the complete set of small-molecule 
chemicals found within a biological sample. The study of metabolic profiles enables the 
measurement of changes in metabolite concentrations, which in turn reflects the biochemical 
effects produced in the organism as a function of disease state or therapeutic intervention.
8,9
 
As a result, metabolic biomarkers can aid early disease detection and provide better 
understanding of disease incidence and progression. Metabolic profiling has proved to be a 
valuable tool for diagnosis and personalised medicine in other areas including 
pharmacology.
10
  
The application of metabolic profiling to the discovery of biomarkers of asthma has been 
explored in biofluids such as urine, plasma and exhaled breath condensate.
11–14
 Saliva 
collection offers distinct advantages as a preferred diagnostic medium; sample collection is 
easy, rapid and non-invasive and does not require specialised training or equipment. Patients 
with significant airflow limitation can perform a passive drool sample which is a major 
advantage in asthma and chronic obstructive pulmonary disease (COPD).  Substances present 
in saliva are biologically active,
15–17
 and saliva has been used for metabolomic studies for 
biomarker discovery in conditions such as physiological stress,
18
 periodontal disease
19
 and 
3 
 
leukoplakia.
20
 We report the development of a rapid method for the metabolic profiling of 
saliva using ultra performance liquid chromatography-mass spectrometry (UHPLC-MS). The 
method has been applied to a pilot study to assess the potential as a tool for asthma diagnosis. 
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2. Methods and materials 
2.1.  Ethical statement 
This research followed the good clinical practices and protocols as approved by the 
Nottingham Research Ethics committee 2 (REC reference number 10/H0408/34). Informed 
consent was obtained for all participants.  
2.2.  Participants 
The participants, 9 people with asthma (3 male and 6 female) and 21 healthy individuals (7 
male and 14 female), were identified from an asthma database held in Nottingham City 
Hospital (Supplementary Fig. S1.). The mean age of the people with asthma was 53 (range 
28-66) and of the healthy controls 35 (range 21-65). (Supplementary Table S1). The 
classification of asthma was based on established diagnostic tests for asthma including forced 
expiratory volume (FEV1%), sputum eosinophil count and methacholine challenge test 
21
 
Participants all had well controlled asthma diagnosed by a consultant respiratory physician 
with a normal asthma control questionnaire
22
 score over the last 3 months, and had not 
required oral steroids within a year. Tests of airway function, including methacholine PC20 
and induced sputum had all been performed between 1 and 6 months prior to saliva collection 
(Supplementary Fig. S1 and Table S1.).  
2.3.  Collection of saliva samples 
Sampling of whole saliva was carried out by the passive drool approach 
23
. Each participant 
was seated with his or her head tilted forward causing saliva to pool in front of his or her 
mouth. Participants were asked not to use their asthma medications or consume alcohol for 
12 hours prior to saliva collection. Participants were also asked to refrain from brushing their 
teeth, having a large meal, drinking tea or coffee and smoking for an hour prior to the sample 
collection. Saliva drooled from the mouth was collected in a glass vial (30mL Chromacol, 
UK) and aliquoted (600 µL) into micro-centrifuge tubes (2.0 mL, LoBind Eppendorf, UK) 
for storage. Equal volume sub-aliquots (600 μL) of saliva from all the participants were 
pooled together, mixed and re-aliquoted as 600 μL aliquots to be used for method 
development and quality control (QC). Samples were stored at -80 ºC immediately after 
aliquoting. 
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2.4.  Chemicals and reagents 
Acetonitrile (analytical grade), water (analytical grade) and formic acid (>99%) were 
purchased from Fisher Scientific (Loughborough, UK). L-carnitine (>99%) and 
hydrocortisone (>99%) were obtained from Sigma-Aldrich (Gillingham, UK). A standard 
mixture of 0.005 mg/mL L-carnitine and hydrocortisone was prepared in water:acetonitrile 
(95:05) (v/v) with 0.1% formic acid. A ToF Reference Mass Solution kit (Agilent 
Technologies, Santa Clara, CA, USA) consisting of purine (m/z 121.0509) and Hexakis(1H, 
1H, 3H-tetrafluoropropoxy)phosphazine (m/z 922.0098) was used to prepare a reference 
mass solution for acquiring accurate mass data. 
2.5.  Sample pre-treatment 
Samples stored at -80 ºC were thawed to room temperature before sample clean-up by protein 
precipitation. Each thawed saliva sample was vortexed for 30 seconds followed by ultra-
sonication for 1 minute to breakdown mucous substances in saliva and to improve 
homogeneity. Protein precipitation was achieved by the addition of 1.2 mL acetonitrile to  
600 μL of saliva i.e. 2:1 ratio of precipitant to saliva 24. The mixture was vortexed for 30 
seconds followed by ultra-sonication for 1 minute and then subjected to centrifugation at 
10,000 g for 10 minutes at ambient temperature. Precipitated proteins from the sample were 
removed as a pellet at the bottom of the microcentrifuge tube. The supernatant was 
transferred to a fresh microcentrifuge tube and evaporated to near dryness (~5 μL) using 
Turbovap LV concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA) prior 
to being reconstituted in 300 μL water/acetonitrile (95:05) (v/v) with 0.1% formic acid. The 
reconstituted saliva extract was placed in a polypropylene micro-insert (Supelco, UK) in an 
autosampler vial (2 mL) for UHPLC-MS analysis. 
2.6.  Instrumentation 
LC-MS analyses were carried out using an Agilent 1200 series HPLC interfaced with an 
Agilent 6230 time-of-flight (TOF) mass spectrometer fitted with a JetStream ESI source 
operated in positive ion mode (Agilent Technologies, Santa Clara, CA, USA). UHPLC 
separation was carried out using a Poroshell 120 EC-C18 column (2.1 mm x 75 mm, 2.7 µm); 
Agilent Technologies, Santa Clara, CA, USA). Poroshell particles have a solid silica core (1.7 
µm) and a porous silica outer layer (0.5 µm thickness), with an end capped C18 bonded phase 
is coated onto the porous outer layer of the particle (Kirkland et al., 2000).  
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Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 0.1% 
formic acid in acetonitrile (v/v). The chromatographic gradient programme was optimised 
using a solution of L-carnitine and hydrocortisone (0.005 mg/mL). The mobile phase flow 
rate was set to 0.5 mL/min. Saliva extracts (10 μL injected) were analysed using an optimised 
chromatographic gradient: 5% B (0-1 min), increased to 30% B (1-10 min). This was 
followed by a column clean-up phase, built into the method to reduce carry over and 
condition the column for analysis of subsequent samples, in which the mobile phase was 
increased to 95% B (10-11 min) and maintained at 95% B (11-12 min) before returning to 
initial conditions (13-15 min). 
MS data were acquired with the instrument mode set to extended dynamic range (2 GHz). 
Mass spectra were acquired in the range m/z 50-1200. The scan rate of the MS was 10 
scans/s. Electrospray source conditions for the mass spectrometer were: sheath gas 
temperature and flow, 350 ºC and 12 L/min; drying gas temperature and flow, 150 ºC and 10 
L/min; nebuliser pressure, 35 psig; transfer capillary, 4000 V; skimmer voltage, 65 V; 
fragmentor voltage, 150 V. A standard solution consisting of purine and hexakis(1H, 1H, 3H- 
tetrafluoropropoxy) phosphazine] was infused via the reference channel of the mass 
spectrometer. The responses from the ions at m/z 121.0509 and m/z 922.0098 were used to 
apply internal mass calibration to the mass spectrum for the analyte channel. 
2.7.  Method development and quality control 
The method workflow is shown in Supplementary Fig. S2. A series of five consecutive 
pooled saliva extracts were analysed prior to the analysis of the control and asthmatic saliva 
to condition the chromatographic column. The metabolomic sample list was randomised prior 
to analysis. A quality control (QC) sample was analysed with every batch of five samples to 
monitor the system stability and data quality. Method blanks were prepared by subjecting 500 
μL of water to the entire sample pre-treatment process and were analysed to assess 
contamination arising from polypropylene microcentrifuge tubes (LoBind Ependorf, UK) and 
polypropylene micro-inserts used during storage and sample pre-treatment. Method blanks 
demonstrated no contamination due to the polypropylene micro-centrifuge tubes and UHPLC 
micro-inserts used for storage, pre-treatment and analysis. 
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2.8.  Data processing 
Mass Hunter Qualitative Analysis software version B.05.00 (Agilent Technologies, Santa 
Clara, CA, USA) was used for processing raw data. Molecular feature extraction (MFE) 
algorithm was used to extract unknown molecular features (MF) and compile a data matrix 
for each sample.  
The generated data matrix consisting of the molecular features from all the samples were 
exported into Mass Profiler Professional software Version 12.05 (Agilent Technologies, 
Santa Clara, CA, USA) for metabolomic data analysis including chromatographic peak 
alignment across multiple LC-MS data files and multivariate statistical analysis. Molecular 
features were extracted using following thresholds: m/z range 50-600 Da; retention time 
range 0.01-10.00 min and mass spectral peak height of ions (centroid data) 100 cps. The 
abundance value for each molecular feature was calculated by MassHunter software as the 
sum of intensities of corresponding isotopic and adducts peaks. The data was normalised to 
the total abundance value within a particular sample for each feature by the software. Data 
filtering and alignment was carried out using following parameters: minimum absolute 
abundance of molecular features 7000 cps, mass alignment window 10 ppm and retention 
time alignment window 0.15 min. 
Stepwise reduction of the number of molecular features was performed based on their 
abundance values and frequency of occurrence in sample classes. Aligned molecular features 
were filtered to reduce the dimensionality of the dataset prior to principal component analysis 
(PCA). In the first instance, only the molecular features present in at least 85% of samples of 
at least one group (i.e. asthma or healthy control) were retained for further processing. In the 
next step, molecular features were filtered based on p-value calculated for each using a 
student’s T-test. Lower p-value signifies higher significant difference between the conditions 
and P ≤ 0.1 was chosen as the filtering criterion to ensure that only the molecular features, 
which differ in their respective conditions with a statistical significance of 90%, were 
retained. The final criterion for filtration of molecular features was the fold change (FC). 
Molecular features, which satisfied the threshold of FC≥2.0, were retained for further 
processing by PCA and to build predictive models. 
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3.  Results and Discussion 
3.1.  UHPLC-MS analysis 
A method has been developed for the rapid metabolic profiling of saliva using ultra 
performance liquid chromatography combined with high resolution mass spectrometry. The 
workflow for the method (Supplementary Fig. S2) and data reporting are consistent with 
proposed standards for metabolomics studies.
25,26
 The method has been applied to a pilot 
study of saliva samples collected by passive drool from asthma patients and controls. Saliva 
extracts were analysed by UHPLC-MS following a protein precipitation step using 
acetonitrile. Protein precipitation was the only sample clean-up process employed in order to 
minimise the effects of discrimination and unpredictable behaviour of unknown metabolites 
during sample preparation.
27
  
A typical LC-MS profile for a saliva extract overlaid with a method blank is shown in Fig. 1 
demonstrating the complexity of the dataset. The chromatographic gradient was adjusted 
using a solution of L-carnitine and hydrocortisone (0.005 mg/mL) such that highly polar L-
carnitine was slightly retained on the column whereas less polar hydrocortisone eluted 
towards the end of the 10 minute chromatographic gradient (data not shown). This enabled all 
the metabolites from saliva extract to be separated within 10 minutes with a typical peak 
width at base of 9 seconds; hence a total analysis time of 15 minutes was achieved, which is 
suitable for a metabolomic study.  
The reproducibility of the method was determined as a part of method development using the 
retention times and chromatographic peak areas of randomly selected ions across the 
chromatographic gradient (Supplementary Table S2 and Fig. S3). The effect of injection 
volumes in the range of 1-20 μL on chromatographic peak areas was analysed using pooled 
saliva extract samples, which were analysed in triplicate. The chromatographic peak areas of 
all the extracted endogenous metabolite ions showed linear responses (R
2 
> 0.989). An 
injection volume of 10 µL was selected from these experiments to be used for the analysis of 
saliva extract, which ensured that the analytical method was capable of detecting small 
positive or negative changes in the metabolite concentrations.  
The reproducibility of the retention times and chromatographic peak areas of extracted 
metabolite ions were assessed from replicate analyses of pooled saliva samples (n=6), using 
the optimised injection volume. Based on replicate measurements (n=6) of five endogenous 
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metabolites, the reproducibility of the retention time and chromatographic peak area was 
determined to be less than 0.4% and 4% respectively (Supplementary Table S2). 
The method developed was applied to the analysis of asthma patient and control saliva 
samples. The resulting dataset were pre-processed and then compared by unsupervised 
multivariate statistical analysis using principal component analysis to identify discriminant 
molecular features. 
3.2.  Data reduction and multivariate analysis 
A molecular feature extractor (MFE) algorithm was employed, because of the complexity of 
the acquired datasets, which enabled the automated extraction of ions corresponding to 
compounds present in saliva samples derived from extracted ion chromatograms. This 
algorithm combines ion species such as multiply charged species, isotopes and adducts 
generated from a single compound into a single molecular feature (MF) to be utilised as a 
single variable in subsequent analysis. 
A total of 35011 molecular features were extracted from all the samples. Out of these, 14267 
were aligned across all the samples from the study. Principal component analysis (PCA) was 
carried out using these 14267 molecular features on all the sample groups from the study 
including conditioning runs and quality control (QC) samples. Clustering of QC samples 
(circled in Fig. 2) provides evidence of consistent and reliable data quality across all the 
samples demonstrating the suitability of the method for metabolic profiling studies. However, 
Fig. 2 shows no clear separation of asthmatic and healthy population; hence, further data 
reduction was required to identify discriminant metabolites between control and asthmatic 
samples.  
Participants with asthma (n=9) were compared against healthy individuals (n=21). The 
dimensionality of the dataset was reduced prior to PCA by filtering the data based on 
frequency of occurrence of molecular features and outcomes of t-test (summarised in a Venn 
diagram in Fig. 3 (a). In the first step, all molecular features which were present in at least 
85% of samples of at least one group (i.e. asthmatic or healthy) were retained. This reduced 
the number of MFs from 14627 to 188. In the next phase, the MFs were filtered based on 
their p-values obtained from a t-test and fold change analysis. MFs, which satisfied the p-
value cut-off value of 0.1 and fold change value of FC≥2.0 were retained as illustrated from 
the volcano plot in Fig 3 (b). This reduced the number of MFs from 188 to 10 
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(Supplementary Table S3). A PCA plot was constructed based on the filtered 10 molecular 
features for moderate asthmatic and healthy control individuals (Fig. 4). The PCA model 
shows clear separation of moderate asthmatics from healthy control samples, with one asthma 
patient sample falling within the control domain. The reasons for this outlier are unknown, 
but this may reflect the known heterogeneity in asthma or be an artefact of the relatively 
small sample set. 
The correlation and covariance of the 10 discriminant features was assessed from an s-plot 
(Supplementary Fig S4). MFs characteristic of asthmatics (i.e. up-regulated) are represented 
in the first quadrant of the plot and the MFs characteristic of healthy control individuals (i.e. 
down-regulated) are shown in the third quadrant of the plot. Table 1 summarises the 
biomarker ions identified from this study. The box and whisker plots for these metabolites are 
provided in Supplementary Figs. S5 and S6. Accurate mass measurement data and isotopic 
ratio data on the discriminant metabolite ions were obtained by analysing a pooled saliva 
extract sample using high resolution mass spectrometry and utilised to obtain tentative 
elemental compositions on the discriminant metabolite ions with a mass widow of 3 ppm 
(Table 1). Putative annotations
25
 for some of the discriminant ions based on physicochemical 
properties (5 ppm mass window and isotope abundance) and spectral similarity with 
metabolome databases are given in supplementary Table S3.
28-30
 Identification of these ions 
requires further investigation involving tandem mass spectrometry and comparison with 
reference standards. Tandem mass spectrometry was not possible with the time-of-flight mass 
analyser used in this work, but the method could be readily adapted for use with a tandem 
mass spectrometer in combination with data dependent or data independent acquisition.  
3.3.  Predictive models 
The discrimination potential offered by the data was evaluated using a widely utilised 
supervised pattern recognition method of partial least squares discriminant analysis (PLS-
DA). A statistical model based on PLS-DA was constructed and validated for classification of 
asthmatic samples. The results of sample classification are presented in Table 2 in terms of 
recognition and prediction abilities, representing the percentage of the samples correctly 
classified during model training and cross-validation. The overall recognition ability during 
training of the model was 80% and for model cross-validation was 96.7%. The model cross 
validation methodology used was k-fold cross-validation with 10 iterations of 3-folds  
(i.e. k=3). These training and cross validation data compare favourably to current tests used 
11 
 
for the diagnosis of asthma.
31,32
 More invasive tests such as bronchial challenge or induced 
sputum are available, but are limited by their invasive nature, cost and need for expertise. 
They also only reflect one aspect of the asthmatic process.
33
 Despite these tests a proper 
diagnosis remains a challenge even in specialist asthma clinics, emphasising the need for a 
non-invasive saliva-based test.
34
 However, further longitudinal studies are required to 
confirm the diagnostic utility of LC-MS in this variable heterogeneous condition.  
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4. Conclusions 
The rapid saliva metabolite profiling method developed in this work allowed discrimination 
between asthma and healthy controls with good sensitivity and reproducibility. To our 
knowledge, this is the first study to employ a passive drool saliva test combined with 
UHPLC-MS as a potential discriminatory tool for asthma. A model derived from 10 
discriminant features classified asthma with an accuracy of ≥ 80% for model training and 
cross-validation. These figures compare favourably to current tests used for the diagnosis of 
asthma.  
The benefits of a simple, non-invasive sampling technique for asthma diagnosis are obvious 
and a great deal of work has focussed on the development of breath sampling, including 
exhaled nitric oxide
35
, measurement of volatile organic compounds
13,36
  and the e-nose 
37
. 
The discriminatory ability of these tests varies.  Importantly the passive drool technique can 
be used in conjunction with or as a preliminary alternative to the existing diagnostic tests 
such as FEV1%, has good discriminatory ability, and provides metabolic information on the 
status of the airway. The identification, validation and the biological significance of the 
discriminant molecular features identified in this study also need to be validated and 
quantified using a larger cohort of moderate and/or severe asthmatics versus healthy control 
populations using a targeted metabolite analysis approach. However, the passive drool 
technique combined with UHPLC-MS offers a novel non-invasive approach to differentiating 
patients with asthma from healthy controls. 
  
13 
 
 Acknowledgements 
The authors wish to acknowledge the Mass Profiler Professional software technical support 
provided by Agilent Technologies, and wish to specially thank Libin Joy at Strand Life 
Sciences Pvt. Ltd. for his help with the software. Authors would also like to thank William 
EP Greenland for training on the MPP software, Wendy Gerrard-Tarpey and Glenn Hearson 
at Nottingham City Hospital for help with sample collection. 
Study funding- The study was funded by an internal grant for the Universities of 
Loughborough and Nottingham. 
Conflicts of interest- The authors declare no conflict of interest.  
14 
 
References 
1.  G. P. Anderson, Lancet, 2008, 372,1107–1419.  
2.  British Thoracic Society, Scottish Intercollegiate Guidelines Network. British 
Guideline on the Management of Asthma: A National Clinical Guideline, 2012. 
3.  D. Shaw, R. Green, M. Berry, S. Mellor, B. Hargadon, M. Shelley et al., Prim. Care 
Respir. J., 2012, 21, 283–2877.  
4.  L-P. Boulet. Curr. Allergy Asthm. R., 2003, 3, 166–171. 
5.  B. Marklund, A. Tunsäter and C. Bengtsson, Fam. Pract., 1999, 16, 112–116.  
6.  S. Wadsworth, D. Sin and D. Dorscheid, J. Asthma Allergy, 2011, 4, 77–86.  
7.  S. J. Szefler, S. Wenzel, R. Brown, S. C. Erzurum, J. V. Fahy, R.G. Hamilton, et al., J. 
Allergy Clin. Immunol., 2012, 129, S9–23. 
8.  J. K. Nicholson and J. C. Lindon, Nature. 2008, 455, 1054–1056.  
9.  A. Smolinska, L. Blanchet, L. M. C. Buydens and S. S. Wijmenga, Anal. Chim. Acta, 
2012, 750, 82–97. 
10.  A. Nordström and R. Lewensohn. J. Neuroimmune Pharmacol., 2010, 5, 4–17. 
11.  E. J. Saude, C. D. Skappak, S. Regush, K. Cook, A. Ben-Zvi, Becker A, et al., J. 
Allergy Clin. Immunol., 2011, 127, 757–764.  
12.  E. Mattarucchi, E. Baraldi and C. Guillou, Biomed. Chrom., 2012, 26, 89–94.  
13.  B. Ibrahim, M. Basanta, P. Cadden, D. Singh, D. Douce, A. Woodcock et al., Thorax 
2011, 66, 804–809. 
14.  S. Carraro, S. Rezzi, F. Reniero, K. Héberger, G. Giordano, S. Zanconato et al., Am J 
Respir Crit Care Med., 2007, 175, 986–990. 
15.  R. Pink, J. Simek, J. Vondrakova, E. Faber, P. Michl, J. Pazdera et al., Biomed. Pap. 
Med. Fac. Univ. Palacky Olomouc Czech Repub., 2009, 153, 103–110.  
16.  A. Zhang, H. Sun and X. Wang. Appl. Biochem. Biotech., 2012, 168, 1718–1727. 
17.  R. G. Schipper, E. Silletti and M. H. Vingerhoeds. Arch. Oral Biol., 2007, 52, 1114–
1135. 
18.  A. Malkar, N. A. Devenport, H. J. Martin, P. Patel, M. A. Turner, P. Watson et al., 
Metabolomics, 2013, 9, 1192-1201. 
15 
 
19.  M. Aimetti, S. Cacciatore, A. Graziano and L. Tenori, Metabolomics, 2011, 8, 465–
474.  
20.  J. Wei, G. Xie, Z. Zhou, P. Shi, Y. Qiu, X. Zheng et al., Int. J. Cancer, 2010 129, 
2207–2217.  
21.  L. J. Fetters and J. I. Matthews, Arch. Intern. Med, 1984, 144, 938–940. 
22.  E. F. Juniper, P. M. O’Byrne, G. H. Guyatt, P. J. Ferrie and D. R. King, Eur. Respir. 
J., 1999, 14, 902–907. 
23.  S. Chiappin, G. Antonelli, R. Gatti and E. F. De Palo, Clin. Chim. Acta, 2007, 383, 30–
40. 
24.  C. Polson, P. Sarkar, B. Incledon, V. Raguvaran and R. Grant,  J. Chromatogr. B, 
2003, 785, 263–275.  
25. L. W. Sumner, A. Amberg, D. Barrett, M. H. Beale, R. Beger et al., Metabolomics, 
2007, 3, 211-221. 
26. R. M. Salek, C. Steinbeck, M. Viant, R. Goodacre and W. B. Dunn, GiggaScience, 
2013, 2, 13-15. 
27.  B. Álvarez-Sánchez, F. Priego-Capote and M. D. Luque de Castro, J. Chromatogr. A,  
2012,  1248, 178–181.  
28. D. S. Wishart, D. Tzur, C. Knox, et al., HMDB: the Human Metabolome Database. 
Nucleic Acids Res. 2007,  35, D521-526. 
29. D. S. Wishart, C. Knox, A. C.  Guo, et al., HMDB: a knowledgebase for the human 
metabolome. Nucleic Acids Res. 2009, 37, D603-610.  
30. D. S. Wishart, T. Jewison, A. C. Guo, M. Wilson, C. Knox et al., HMDB 3.0 — The 
Human Metabolome Database in 2013. Nucleic Acids Res. 2013, 41, D801-817. 
31  C. J. Hunter, C. E. Brightling, G. Woltmann, A. J. Wardlaw and I. D. Pavord. Chest, 
2002, 121, 1051–1057.  
32.  V. P. Luks, K. L. Vandemheen and S. D. Aaron, Eur. Respir. J.,  2010, 36, 255–260.  
33.  C. L. Grainge, L. C. K. Lau, J. A. Ward, V. Dulay, G. Lahiff,. Wilson S, et al., N. 
Engl. J. Med., 2011, 364, 2006–2015.  
34.  D. S. Robinson, D. A. Campbell, S. R. Durham, J. Pfeffer, P. J. Barnes and K. F. 
Chung, Eur. Respir. J., 2003, 22, 478–483.  
35. D. E. Shaw, M. Berry, M. Thomas, R. H. Green, C. E. Brightling, Wardlaw AJ, et al.,     
Am J Respir Crit Care Med., 2007, 176, 231–237. 
16 
 
36. P. Montuschi, M. Santonico, C. Mondino, G. Pennazza, G. Mantini, E. Martinelli, et 
al., Chest, 2007, 137, 790–796. 
37. S. Dragonieri, O. Tongoussouva, A. Zanini, A. Imperatori and A. Spanevello, Monaldi 
Arch. Chest Dis., 2009, 71, 119–126. 
  
17 
 
 
Table 1. Discriminant molecular features (MFs) obtained from moderate asthmatics 
versus control samples. 
Marker 
No. 
Retention 
Time (min) 
m/z 
 
Regulation Proposed elemental 
composition 
 
1 0.4 116.0699 Up C5H9NO2  
2 2.2 261.1446 Up C12H23N3O5  
3 1.1 290.1711 Up C11H20N2O5  
4 3.6 316.2217 Up C15H29N3O4  
5 4.4 439.4569 Up Unidentified
a
  
6 3.4 227.1268 Down C12H18O4  
7 4.7 573.2561 Down C26H44N4O4S3  
8 0.5 596.3253 Down C28H41N11O2S  
9 1.7 345.1163 Down C22H17ClN2  
10 5.5 227.1396 Down C11H18N2O3  
a 
No elemental composition computed within ± 3 ppm mass window. 
  
18 
 
Table 2. Classification results obtained by PLS-DA model for asthma patients and 
controls. 
 
Predicted Asthmatic Predicted Controls Accuracy (%) 
Model Training 
  
True Moderate Asthmatic 8 1 88.9 
True Controls 5 16 76.2 
Recognition ability 
  
80.0 
Model cross-validation 
  
True Moderate Asthmatic 9 0 100.0 
True Controls 1 20 95.2 
Recognition ability 
  
96.7 
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5. List of Figures 
Fig 1. LC-MS analysis of a saliva extract showing the total ion chromatogram (TIC) for the 
saliva extract (red trace) and a method blank (black trace). 
Fig 2. Principal component analysis 3D plot of saliva samples from the study coloured 
according to sample groups. X-Axis: Component 1 (20.07%), Y-Axis: Component 2 
(13.26%) and Z-Axis: Component 3 (6.44%). 
Fig 3. a) Summary of data reduction based on frequency of molecular features in samples, b) 
volcano plot illustrating filtering of molecular features based on the results of t-test and fold 
change analysis (P value cut off 0.1 and fold change cut off 2.0) 
Fig 4. Principal component analysis 3D plot of saliva samples from moderate asthmatics 
(red) and healthy control samples (blue). X-Axis: Component 1 (49.08%); Y-Axis: 
Component 2 (15.47%) and Z-Axis: Component 3 (12.02%). 
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6. FIGURES 
 
Fig. 1. LC-MS analysis of a saliva extract showing the total ion chromatogram (TIC) for 
the saliva extract (red trace) and a method blank (black trace). 
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Fig 2. Principal component analysis 3-D plot of saliva samples from the study coloured 
according to sample groups. X-Axis: Component 1 (20.07%), Y-Axis: Component 2 
(13.26%) and Z-Axis: Component 3 (6.44%). 
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Fig 3. a) Summary of data reduction based on frequency of molecular features in 
samples, b) Volcano plot illustrating filtering of molecular features based on the results 
of T-test and fold change analysis (P value cut off 0.1 and fold change cut off 2.0) 
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Fig 4. Principal component analysis 3-D plot of saliva samples from moderate 
asthmatics (red) and healthy control samples (blue). X-Axis: Component 1 (49.08%); Y-
Axis: Component 2 (15.47%) and Z-Axis: Component 3 (12.02%). 
 
